MedTrace Logo

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

NCT07662018 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-06-23

No results posted yet for this study

Summary

To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.

Conditions

  • Prospective Observational Study
  • Gemcitabine
  • Docetaxel
  • Melphalan
  • Carboplatin
  • Stem Cell Transplantation
  • Pediatric Relapsed
  • Refractory Germ

Interventions

DRUG

Gemcitabine (GEM)

Give by Iv

DRUG

Docetaxel

Given by Iv

DRUG

Melphalan

Given by IV

DRUG

Carboplatin

Given by Iv

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Irtiza N Sheikh, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-05
Primary Completion
2031-12-31
Completion
2033-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07662018 on ClinicalTrials.gov